Recent Advances in Treatment and Radiation Therapy of Breast Cancer
DOI:
https://doi.org/10.48111/2021.02.04Keywords:
Breast cancer, Estrogen Receptor, Progesterone receptor, Chemotherapy, human epidermal growth factor receptor 2, RadiotherapyAbstract
This review of literature will cover the recent advances in treatment of breast cancer. It will cover the molecular subtypes of breast cancer and treatment advancements in each subtype of breast cancer precisely. The role of neoadjuvant chemotherapy and advances in surgical techniques will also be discussed. One major aspect of breast cancer treatment is management of axilla, recent studies about axillary management will also be discussed. At the end there will be brief description about modern radiotherapy treatment schedules and techniques.
References
Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786-3788. doi:10.3322/caac.21387.
Siegal R, Miller KD, Jemal A. Cancer statistics, 2012. Ca Cancer J Clin. 2014;64(1):9-29. doi:10.1172/JCI60534.
Wang SE, Sun YD, Zhao SJ, Wei F, Yang G. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients. Math Biosci Eng MBE. 2019;17(1):92-104. doi: 10.3934/mbe.2020005.
De Rose F, Fogliata A, Franceschini D, et al. Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. Med Oncol. 2019;36(6):1-8. doi: 10.1007/s12032-019-1275-z.
Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. doi: 10.1016/S0140-6736(05)66544-0.
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816 doi: 10.1016/S0140-6736(12)61963-1.
Sanz A, Del Valle ML. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years. N Engl J Med. 2016;375(16):1590. doi: 10.1016/S0140-6736(04)17666-6.
Howell A. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60-62. doi: 10.1056/NEJMoa1604700.
Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005;97(17):1262-1271. doi: 10.1093/jnci/dji250.
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748. doi: 10.1056/NEJMoa1609709.
Sledge Jr GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2? advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585.
Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017;165(3):573-583. doi: 10.1007/s10549-017-4358-6.
Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(10):1134. doi: 10.1200/JCO.2015.65.2289.
Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-820. doi: 10.1056/NEJMoa0910383.
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283. doi: 10.1056/NEJMoa053028.
Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9.
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284. doi: 10.1093/annonc/mdt182.
Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734. doi: 10.1056/NEJMoa1413513.
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281. doi:10.1200/JCO.2007.14.4147.
Berrada N, Delaloge S, Andre F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010;21:vii30-vii35. doi:10.1093/annonc/mdq279.
Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab+ nab-paclitaxel vs placebo+ nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2020;31:S1148. doi: 10.1016/j.annonc.2020.08.2244.
Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544-2552. doi: 10.1002/cncr.29348.
Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220(6):1063-1069. doi: 10.1016/j.jamcollsurg.2015.02.011.
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549-555. doi: 10.1001/jamaoncol.2016.4163.
Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5.
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232. doi: 10.1056/NEJMoa020989.
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-933. doi: 10.1016/S1470-2045(10)70207-2.
Giuliano AE, Ballman K V, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. Jama. 2017;318(10):918-926. doi: 10.1097/SAP.0b013e31827e5333.
Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013;70(4):435-437. doi: 10.1001/jama.2017.11470.
Mast ME, van Kempen-Harteveld L, Heijenbrok MW, et al. Left-sided breast cancer radiotherapy with and without breath-hold: Does IMRT reduce the cardiac dose even further? Radiother Oncol. 2013;108(2):248-253. doi: 10.1016/S1470-2045(14)70460-7.
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Jama. 2013;310(14):1455-1461. doi: 10.1001/jama.2013.278932.
Morrow M, Dang CT. Sentinel node biopsy after neoadjuvant chemotherapy: a new standard for patients with axillary metastases? JAMA. 2013;310(14):1449-1450 doi: 10.1001/jama.2013.7844.
James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev. 2010;(11). doi: 10.1002/14651858.
Chitapanarux I, Klunklin P, Pinitpatcharalert A, et al. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019;14(1):1-10. doi: 10.1186/s13014-019-1378-x.
Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73-79. doi: 10.1016/j.prro.2016.09.007.
Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8.
Piroth MD, Baumann R, Budach W, et al. Heart toxicity from breast cancer radiotherapy. Strahlentherapie und Onkol. 2019;195(1):1-12. doi: 10.1007/s00066-018-1378-z.
Jan Haussmann, Stefanie Corradini, Carolin Nestle-Kraemling,et al. Recent advances in radiotherapy of breast cancer.Radiation Oncology 2020.15:71. doi10.1186/s13014-020-01501-x.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Ahmad Farooq, Misbah Masood, Abu Baker Shahid
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
